XLRN - Why Acceleron Pharma Stock Bolted Higher in January
Shares of the mid-cap drugmaker Acceleron Pharma (NASDAQ: XLRN) gained a staggering 71.2% during the month of January, according to data from S&P Global Market Intelligence. The biotech's stock skyrocketed late last month in response to positive midstage trial results for experimental pulmonary arterial hypertension (PAH) drug sotatercept.
PAH is a rare but serious disorder characterized by abnormally high blood pressure in the lungs. The underlying cause of PAH is a mystery in most cases, but it has been associated with a host of ailments like HIV infection, autoimmune disorders, and even drug-related side effects.
Image source: Getty Images.